A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Brief description of study

The purpose of the study is to evaluate the anti-tumor activity of pembrolizumab with fulvestrant for subjects with metastatic, hormone receptor positive, HER2 negative breast cancer. The study drug pembrolizumab is investigational in this study, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s21-01676
ClinicalTrials.gov Identifier: NCT03393845

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.